Login
Companies $ANNX
$3.61 +$0.04 (1.12%) After hours
Annexon, Inc. logo

Annexon, Inc.

annexonbio.com

What Do They Do?

Develops targeted immunotherapies for autoimmune, neurodegenerative and eye diseases by blocking the classical complement pathway.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +7% (Loss)
vs −$54.9M in Q3 FY2025

Portfolio priorities The older report described active programs across GBS, Huntington’s disease, GA and autoimmune indications. The latest report emphasizes late-stage candidates for GBS and GA alongside an oral drug for autoimmune conditions.

Who Do They Compete With?

Competes with Hansa Biopharma, AstraZeneca, Alexion, argenx, Apellis, Astellas, Regeneron, Aviceda Therapeutics, Janssen, Novartis, Perceive Bio, Roche, Alkeus, Belite Bio, Stealth BioTherapeutics, Boehringer Ingelheim, Galimedix Therapeutics, Cognition Therapeutics, ONL Therapeutics, and Ocugen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support